{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:13:44Z","timestamp":1788686024499,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Strategic Priority Research Program of CAS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The successive emergences and accelerating spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages and evolved resistance to some ongoing clinical therapeutics increase the risks associated with the coronavirus disease 2019 (COVID-19) pandemic. An urgent intervention for broadly effective therapies to limit the morbidity and mortality of COVID-19 and future transmission events from SARS-related coronaviruses (SARSr-CoVs) is needed. Here, we isolate and humanize an angiotensin-converting enzyme-2 (ACE2)-blocking monoclonal antibody (MAb), named h11B11, which exhibits potent inhibitory activity against SARS-CoV and circulating global SARS-CoV-2 lineages. When administered therapeutically or prophylactically in the hACE2 mouse model, h11B11 alleviates and prevents SARS-CoV-2 replication and virus-induced pathological syndromes. No significant changes in blood pressure and hematology chemistry toxicology were observed after injections of multiple high dosages of h11B11 in cynomolgus monkeys. Analysis of the structures of the h11B11\/ACE2 and receptor-binding domain (RBD)\/ACE2 complexes shows hindrance and epitope competition of the MAb and RBD for the receptor. Together, these results suggest h11B11 as a potential therapeutic countermeasure against SARS-CoV, SARS-CoV-2, and escape variants.<\/jats:p>","DOI":"10.1038\/s41467-021-25331-x","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:05:02Z","timestamp":1629194702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants"],"prefix":"10.1038","volume":"12","author":[{"given":"Yanyun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-8004","authenticated-orcid":false,"given":"Fengze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-2666","authenticated-orcid":false,"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-8889","authenticated-orcid":false,"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-1385","authenticated-orcid":false,"given":"Yue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-1701","authenticated-orcid":false,"given":"Junyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-1136","authenticated-orcid":false,"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5141","authenticated-orcid":false,"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-3066","authenticated-orcid":false,"given":"Chenhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-3829","authenticated-orcid":false,"given":"Jinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"25331_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"25331_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894\u2013904.e899 (2020).","journal-title":"Cell"},{"key":"25331_CR3","doi-asserted-by":"publisher","first-page":"e01933","DOI":"10.1128\/JVI.01933-17","volume":"92","author":"A Milewska","year":"2018","unstructured":"Milewska, A. et al. Entry of human coronavirus NL63 into the cell. J. Virol. 92, e01933\u201317 (2018).","journal-title":"J. Virol."},{"key":"25331_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"25331_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1126\/science.abe2402","volume":"370","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110\u20131115 (2020).","journal-title":"Science"},{"key":"25331_CR6","unstructured":"FDA. Emergency Use Authorization. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization (2021)."},{"key":"25331_CR7","doi-asserted-by":"publisher","first-page":"1854149","DOI":"10.1080\/19420862.2020.1854149","volume":"12","author":"M Tuccori","year":"2020","unstructured":"Tuccori, M. et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 12, 1854149 (2020).","journal-title":"MAbs"},{"key":"25331_CR8","doi-asserted-by":"crossref","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","DOI":"10.1038\/s41586-021-03398-2"},{"key":"25331_CR9","doi-asserted-by":"crossref","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature medicine 27, 917\u2013924 (2021).","DOI":"10.1038\/s41591-021-01318-5"},{"key":"25331_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"25331_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"25331_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tim.2015.06.003","volume":"23","author":"G Lu","year":"2015","unstructured":"Lu, G., Wang, Q. & Gao, G. F. Bat-to-human: spike features determining \u2018host jump\u2019 of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 23, 468\u2013478 (2015).","journal-title":"Trends Microbiol."},{"key":"25331_CR13","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1128\/JVI.01394-09","volume":"84","author":"RL Graham","year":"2010","unstructured":"Graham, R. L. & Baric, R. S. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J. Virol. 84, 3134\u20133146 (2010).","journal-title":"J. Virol."},{"key":"25331_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair, H. A. Ibalizumab: a review in multidrug-resistant HIV-1 infection. Drugs 80, 189\u2013196 (2020).","journal-title":"Drugs"},{"key":"25331_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu, B. et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N. Engl. J. Med. 379, 645\u2013654 (2018).","journal-title":"N. Engl. J. Med."},{"key":"25331_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"25331_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"25331_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","volume":"183","author":"L Yurkovetskiy","year":"2020","unstructured":"Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739\u2013751.e738 (2020).","journal-title":"Cell"},{"key":"25331_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"25331_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","volume":"6","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 11 (2020).","journal-title":"Cell Discov."},{"key":"25331_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi, M. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th Anniversary of the Discovery of ACE2. Circulation Res. 126, 1456\u20131474 (2020).","journal-title":"Circulation Res."},{"key":"25331_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/1440-1681.13251","volume":"47","author":"T Qaradakhi","year":"2020","unstructured":"Qaradakhi, T. et al. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. Clin. Exp. Pharmacol. Physiol. 47, 751\u2013758 (2020).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"25331_CR23","doi-asserted-by":"publisher","unstructured":"Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.2012.2021.20248640 (2020).","DOI":"10.1101\/2020.2012.2021.20248640"},{"key":"25331_CR24","doi-asserted-by":"crossref","unstructured":"Graham, M. S. et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 6, e335\u2013e345 (2021).","DOI":"10.1016\/S2468-2667(21)00055-4"},{"key":"25331_CR25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294.e1289 (2020).","journal-title":"Cell"},{"key":"25331_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133.e124 (2020).","journal-title":"Cell Host Microbe"},{"key":"25331_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li, C. W. et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33, 187\u2013201.e110 (2018).","journal-title":"Cancer Cell"},{"key":"25331_CR28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.bbrc.2016.06.131","volume":"477","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth. Biochem. Biophys. Res. Commun. 477, 755\u2013760 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"25331_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905\u2013913.e907 (2020).","journal-title":"Cell"},{"key":"25331_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.abc0870","volume":"369","author":"KK Chan","year":"2020","unstructured":"Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261\u20131265 (2020).","journal-title":"Science"},{"key":"25331_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41422-020-00450-0","volume":"31","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res. 31, 17\u201324 (2021).","journal-title":"Cell Res."},{"key":"25331_CR32","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","volume":"26","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med. 26, 1422\u20131427 (2020).","journal-title":"Nat. Med."},{"key":"25331_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384.e16 (2020).","journal-title":"Cell"},{"key":"25331_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","volume":"182","author":"C Kreer","year":"2020","unstructured":"Kreer, C. et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 843\u2013854.e812 (2020).","journal-title":"Cell"},{"key":"25331_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"25331_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"25331_CR37","doi-asserted-by":"publisher","unstructured":"Dong, J. et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.01.27.428529 (2021).","DOI":"10.1101\/2021.01.27.428529"},{"key":"25331_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238\u2013251 (2021).","journal-title":"N. Engl. J. Med."},{"key":"25331_CR39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632\u2013644 (2021).","journal-title":"JAMA"},{"key":"25331_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"25331_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/prot.340100306","volume":"10","author":"RH Yun","year":"1991","unstructured":"Yun, R. H., Anderson, A. & Hermans, J. Proline in alpha-helix: stability and conformation studied by dynamics simulation. Proteins 10, 219\u2013228 (1991).","journal-title":"Proteins"},{"key":"25331_CR42","doi-asserted-by":"publisher","first-page":"e00535","DOI":"10.1002\/prp2.535","volume":"7","author":"MS Castelli","year":"2019","unstructured":"Castelli, M. S., McGonigle, P. & Hornby, P. J. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol. Res. Perspect. 7, e00535 (2019).","journal-title":"Pharmacol. Res. Perspect."},{"key":"25331_CR43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"25331_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr."},{"key":"25331_CR45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr D"},{"key":"25331_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","volume":"10","author":"LA Kelley","year":"2015","unstructured":"Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845\u2013858 (2015).","journal-title":"Nat. Protoc."},{"key":"25331_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D"},{"key":"25331_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nmeth.2648","volume":"10","author":"F DiMaio","year":"2013","unstructured":"DiMaio, F. et al. Improved low-resolution crystallographic refinement with Phenix and Rosetta. Nat. Methods 10, 1102\u20131104 (2013).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25331-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:52:56Z","timestamp":1669989176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25331-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25331"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25331-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.D., R.S., C.W., and J.Y. are listed as inventors on pending patent applications for h11B11. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5000"}}